Fatima Karzai

19PUBLICATIONS
128CO-AUTHORS
Molecular targetsLiquid biopsiesRadiation therapyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 24, 2026
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.

|Jul 01, 2026
PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.

|Mar 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li, Ravi A Madan, Min-Jung Lee

|Feb 12, 2026
Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancer.

Chennan Li, Anna Baj, Clara C Y Seo

|Jan 13, 2026
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.

Surendra Gulla, Tej Sharma, Ephraim Gardner

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

Pageof 4

Frequent Collaborators

12 joint publications

Ravi A Madan

9 joint publications

James L Gulley

7 joint publications

Adam Sowalsky

6 joint publications

Jeffrey Schlom